HIV

Despite inducing anti-HIV antibodies, vaccine in HVTN 505 trial still not protective.

Liver damage progresses at a more rapid pace in patients with HIV.

Compound reduces residual levels from infected dormant cells.

Test distinguishes between HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens.

The first diagnostic test that can differentiate between types of HIV infection has been approved by the FDA.

Antibodies critical to stopping spread of viral cells.

The dispensing model for pyrimethamine has changed, which may cause delays in therapy.

Complete protection seen in half of non-human primates vaccinated against repeated challenges with simian immunodeficiency virus.

The once-daily, single-tablet regimen is the third tenofovir alafenamide-based HIV treatment from Gilead Sciences.

Study finds current efforts are not enough to decrease the spread of infection.

Early research in HIV and hepatitis B discontinued.

Half of patients evaluated had scores that would classify them as clinically depressed.

Pharmacists can reassure patients taking pre-exposure prophylaxis that the human immunodeficiency virus prevention treatment will not increase their risk for depression.

Study finds greater unmet needs for basic services compared with male patients.

Marketplace users less likely to use most medication classes except for hepatitis C and HIV.

Discovery may accelerate search for effective vaccine.

Persistent HIV reservoirs present ongoing treatment challenge.

Drug mitigates elevated cardiovascular risk in infected patients.

Blood test predicts which patients will respond to interferon.

Study finds chronic hepatitis C has a limited impact on mortality unless the patient has other severe comorbidities.

HIV and HCV co-infected patients with HALS found to be more likely to develop cirrhosis.

Liver damage is the bane of HIV-infected patients' existence.

A look back at the top stories on Specialty Pharmacy Times from May 4 to May 8.

Implant delivers sustained release of ARV drugs up to 40 days with no adverse side effects.

Age-related macular degeneration greater in HIV-infected patients.

Vangardist, a monthly men's magazine, is releasing 3000 copies of its spring issue, which will feature ink infused with HIV-positive blood donated by 3 individuals.

Patients with AIDS face a 4-fold greater risk of age-related macular degeneration (AMD) than their HIV-uninfected counterparts.

Boosting immune system improves efficacy of antiretroviral drugs.

Delays can negatively affect treatment efficacy and the risk of morbidity and mortality among patients.

Expanded hours may be needed to overcome treatment obstacles.